<DOC>
	<DOCNO>NCT00308516</DOCNO>
	<brief_summary>This phase II trial investigate combination adjuvant 5-fluorouracil , radiation , bevacizumab patient stage II III rectal cancer , follow FOLFOX6 bevacizumab . Fluorouracil ( FU ) proven effective safe regimen treatment stage II III rectal cancer . Recent evidence proven fluorouracil/leucovorin ( FL ) combination bevacizumab superior FL alone combine irinotecan superior ( irinotecan plus fluorouracil/leucovorin ( IFL ) alone . This trial one first clinical trial evaluate combination target therapy , radiation , chemotherapy adjuvant treatment common solid tumor .</brief_summary>
	<brief_title>5-Fluorouracil , Bevacizumab , Radiation Followed Modified FOLFOX6 Bevacizumab Stage II/III Rectal Cancer</brief_title>
	<detailed_description>All eligible patient receive combine modality treatment initially . Systemic treatment begin 4-6 week completion Combined Modality portion complete 4 cycle 4 week regimen . Patients evidence disease follow systemic therapy may continue single agent bevacizumab one year . After treatment complete , patient re-evaluated image establish new baseline . Patients re-evaluated thereafter total 5 year . Combined Modality Treatment : - bevacizumab 5mg/kg IV infusion day 1 , 15 , 29 - fluorouracil 225mg/m2 IV continuous infusion day 1-42 - radiation 1.8 Gy/day 28 fraction week 1-6 Systemic Treatment : - 5-fluorouracil 400 mg/m2 bolus - 5-fluorouracil 2400 mg/m2 46 hour day 1 15 - leucovorin 350 mg prior FU day 1 15 - oxaliplatin 85 mg/m2 day 1 15 - bevacizumab 5 mg/kg day 1 15</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm Stage I II rectal cancer Patients must candidate preoperative adjuvant chemoradiation . Patients enrol adjuvant chemoradiation cohort must undergo surgical resection primary rectal tumor 28 56 day ( i.e. , 48 week ) prior study treatment . ECOG performance status 01 Adequate bone marrow , liver , kidney function At least 18 year age Able give write informed consent Treatment prior chemotherapy radiation rectal cancer History myocardial infarction Uncontrolled hypertension , unstable angina , congestive heart failure , serious cardiac arrhythmia require medication peripheral vascular disease History stroke within 6 month History abdominal fistula , gastrointestinal perforation , intrabdominal abscess within 6 month Symptomatic sensory peripheral neuropathy Prior treatment antiangiogenic agent Prior malignancy past 5 year Active infection serious underlie medical condition Major surgery le 28 day prior Women pregnant lactate Thrombolytic therapy within 10 day start bevacizumab PEG tube , Gtube , external biliary stent Proteinuria Non heal wound , ulcer fracture History bleed diathesis coagulopathy Hemoptysis Participation another experimental trial within 28 day Uncontrolled anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rectal Cancer</keyword>
	<keyword>Cancer Rectum</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>